Genentech

J&J cancer med adds indication, lower dose

J&J cancer med adds indication, lower dose

By

The fast-tracked drug netted another indication today, this one for a form of leukemia. Lower dosage of the drug for that indication shrinks the price compared to lymphoma.

Roche's Rituxan successor receives high marks

By

Genentech's blockbuster follow-up shows promise in preliminary Phase III data

Email Newsletters